|Description||AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases,|
Avitinib maleate, the maleate salt form of avitinib, is a pyrrolopyrimidine-based, irreversible epidermal growth factor receptor (EGFR) mutant-selective inhibit...
This active molecular is an irreversible EGFR ( epidermal growth factor receptor ) tyrosine kinase inhibitor. Transtinib shows good anti-proliferative activity ...
Pelitinib is a 3-cyanoquinoline pan-ErbB tyrosine kinase inhibitor with potential antineoplastic activity. EKB-569 irreversibly binds covalently to epidermal gr...
EGF816, also called as Nazartinib, a covalent mutant-selective EGFR inhibitor and potently inhibits the T790M resistance mutation while sparing wild-type EGFR. ...
AZ5104, the demethylated metabolite of AZD-9291, is a potent EGFR inhibitor with IC50 of
Falnidamol, also known as BIBX 1382, is a pyrimido-pyrimidine with antitumor activity. BIBX 1382 inhibits the intracellular tyrosine kinase domain of the Epider...
AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become ...
Dacomitinib, aslo known as PF-299 and PF-00299804; or PF299804, is an orally bioavailable, highly selective, second-generation small-molecule inhibitor of the p...
Varlitinib, also known as ARRY-543, is an orally bioavailable inhibitor of the epidermal growth factor receptor family with potential antineoplastic activity. V...
Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
WZ-3146 is an irreversiblely inhibitor against EGFR T790M with potential anticancer activity.
EGF816 mesylate is the mesylate salt of EGF816 which is a covalent mutant-selective EGFR inhibitor and potently inhibits the T790M.
AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-ove...
Gefitinib Hcl(ZD-1839 Hcl) is an EGFR inhibitor, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells.
Afatinib Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, res...
PF-06459988 is a third-generation, irreversible epidermal growth factor receptor (EGFR) inhibitor. It can bind to and inhibit mutant forms of EGFR, including th...
SKLB1028 is a novel Bcr-abl tyrosine kinase inhibitor, Epidermal growth factor inhibitor and Fms-like tyrosine kinase 3 inhibitor originated by CSPC Ouyi Pharma...
AG 556, a dihydroxyphen derivative, has been found to be a EGFR kinase inhibitor that could probably be effective in the study of myocardial infarct and hemodyn...
EAI045 is an allosteric, non-ATP competitive inhibitor of mutant EGFR. In vitro studies proved that EAI045 is active and selective for T790M- harboring EGFR mut...